Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05987332 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 56 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: 2 to 3 Trial status: Recruiting to Active, Not Recruiting · Eligibility criteria expanded, about 34 words · Secondary endpoints: 8 to 11 · 2 morev56 Show 5 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Eligibility criteria expanded, about 34 words
    • Secondary endpoints: 8 to 11
    • Study description expanded, about 9 words
    • Site details revised at 68 of 68 sites

    See this version in full on ClinicalTrials.gov ↗

  2. Site contacts updated at 1 of 68 sitesv55
  3. Study sites: 67 to 68v54
  4. Site details revised at 3 of 67 sitesv53
  5. Study sites: 66 to 67v52
Show 45 earlier versionsHide 45 earlier versions
  1. Site details revised at 1 of 66 sitesv51
  2. Site details revised at 3 of 66 sitesv50
  3. Site details revised at 1 of 66 sitesv49
  4. Site details revised at 1 of 66 sitesv48
  5. Site details revised at 3 of 66 sitesv47
  6. Site details revised at 1 of 66 sitesv46
  7. Site contacts updated at 1 of 66 sitesv45
  8. Site details revised at 1 of 66 sitesv44
  9. Site details revised at 1 of 66 sitesv43
  10. Site details revised at 1 of 66 sitesv42
  11. Site details revised at 2 of 66 sitesv41
  12. Site details revised at 6 of 66 sitesv40
  13. Enrollment target: 380 to 420 Eligibility criteria expanded, about 33 wordsv39 Show 1 more changeShow less
    • Eligibility criteria expanded, about 33 words

    See this version in full on ClinicalTrials.gov ↗

  14. Site details revised at 5 of 66 sitesv38
  15. Site details revised at 4 of 66 sitesv37
  16. Site contacts updated at 1 of 66 sitesv36
  17. Study sites revised (66)v35 See this version in full on ClinicalTrials.gov ↗
  18. Site details revised at 1 of 66 sitesv34
  19. Site details revised at 1 of 66 sitesv33
  20. Site details revised at 1 of 66 sitesv32
  21. Site details revised at 1 of 66 sitesv31
  22. Site details revised at 1 of 66 sitesv30
  23. Site contacts updated at 3 of 66 sitesv29
  24. Study sites: 65 to 66v28
  25. Study sites: 63 to 65v27
  26. Site details revised at 1 of 63 sitesv26
  27. Site contacts updated at 1 of 63 sitesv25
  28. Site details revised at 1 of 63 sitesv24
  29. Site contacts updated at 1 of 63 sitesv23
  30. Site details revised at 1 of 63 sitesv22
  31. Site details revised at 2 of 63 sitesv21
  32. Site details revised at 3 of 63 sitesv20
  33. Site details revised at 2 of 63 sitesv19
  34. Site details revised at 17 of 63 sitesv18
  35. Site details revised at 10 of 63 sitesv17
  36. Site details revised at 1 of 63 sitesv16
  37. Site details revised at 5 of 63 sitesv15
  38. Study sites: 54 to 63v14
  39. Study sites: 55 to 54v13
  40. Study sites: 54 to 55v12
  41. Site details revised at 2 of 54 sitesv11
  42. Study sites revised (54)v10 See this version in full on ClinicalTrials.gov ↗
  43. Study sites: 47 to 54v9
  44. Start date changed from estimate of Oct 2023 to Oct 31, 2023 Site contacts updated at 1 of 47 sitesv8 Show 1 more changeShow less
    • Site contacts updated at 1 of 47 sites
  45. Study sites: 28 to 47v7
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
IDEAYA Biosciences
11 trials monitored
See all monitored trials
Melanoma
1,026 trials monitored
See 48 trials at risk
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
Trial Details
NCT Number NCT05987332
Lead Sponsor IDEAYA Biosciences
Conditions Metastatic Uveal Melanoma
Enrollment 420 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov